Cited by 599Viral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 ResearchPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Open access

Mevorach, Dror, Anis, Emilia, Cedar, Noa, Bromberg, Michal, Haas, Eric J., Nadir, Eyal, Olsha-Castell, Sharon, Arad, Dana, Hasin, Tal, Levi, Nir, Asleh, Rabea, Amir, Offer, Meir, Karen, Cohen, Dotan, Dichtiar, Rita, Novick, Deborah, Hershkovitz, Yael, Dagan, Ron, Leitersdorf, Iris, Ben-Ami, Ronen, Miskin, Ian, Saliba, Walid, Muhsen, Khitam, Levi, Yehezkel, Green, Manfred S., Keinan-Boker, Lital, Alroy-Preis, Sharon·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2109730PMC PMC8531987

Open this paper in CoChat — free account

Abstract

BACKGROUND: Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. METHODS: We retrospectively reviewed data obtained from December 20, 2020, to May 31, 2021, regarding all cases of myocarditis and categorized the information using the Brighton Collaboration definition. We analyzed the occurrence of myocarditis by computing the risk difference for the comparison of the incidence after the first and second vaccine doses (21 days apart); by calculating the standardized incidence ratio of the observed-to-expected incidence within 21 days after the first dose and 30 days after the second dose, independent of certainty of diagnosis; and by calculating the rate ratio 30 days after the second dose as compared with unvaccinated persons. RESULTS: Among 304 persons with symptoms of myocarditis, 21 had received an alternative diagnosis. Of the remaining 283 cases, 142 occurred after receipt of the BNT162b2 vaccine; of these cases, 136 diagnoses were definitive or probable. The clinical presentation was judged to be mild in 129 recipients (95%); one fulminant case was fatal. The overall risk difference between the first and second doses was 1.76 per 100,000 persons (95% confidence interval [CI], 1.33 to 2.19), with the largest difference among male recipients between the ages of 16 and 19 years (difference, 13.73 per 100,000 persons; 95% CI, 8.11 to 19.46). As compared with the expected incidence based on historical data, the standardized incidence ratio was 5.34 (95% CI, 4.48 to 6.40) and was highest after the second dose in male recipients between the ages of 16 and 19 years (13.60; 95% CI, 9.30 to 19.20). The rate ratio 30 days after the second vaccine dose in fully vaccinated recipients, as compared with unvaccinated persons, was 2.35 (95% CI, 1.10 to 5.02); the rate ratio was again highest in male recipients between the ages of 16 and 19 years (8.96; 95% CI, 4.50 to 17.83), with a ratio of 1 in 6637. CONCLUSIONS: The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2109730

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citation
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., Grinberg, T., Auster, O., Dagan, N., Balicer, R. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110737 · Cited by 613
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System
Mei, R., Raschi, E., Forcesi, E., Diemberger, I., Ponti, F. D., & Poluzzi, E. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.054 · Cited by 84
Surveillance Guidelines for Smallpox Vaccine (vaccinia) Adverse Reactions
Casey, C., Vellozzi, C. J., Mootrey, G. T., Chapman, L. E., McCauley, M. M., Roper, M. H., Damon, I. K., & Swerdlow, D. L. (2006) · PsycEXTRA Dataset · doi:10.1037/e506942006-001 · Cited by 58
Update: Cardiac-Related Events During the Civilian Smallpox Vaccination Program— United States, 2003
(2003) · JAMA · doi:10.1001/jama.290.1.31 · Cited by 41

Flagged first, then by citations

Show all 7 references

Research works printed but not linked: 1

Sahai H Khurshid A. Statistics in epidemiology: methods techniques and applications. Boca Raton FL: CRC Press 1996.

Sorted by citations

Items 201–300 of 598

COVID-19 and Acute Cardiac Injury: Clinical Manifestations, Biomarkers, Mechanisms, Diagnosis, and Treatment
Qiu, H., Li, J., Li, J., Li, H., & Xin, Y. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01902-w · Cited by 12
Myopericardial complications following COVID-19 disease and vaccination: a clinical consensus statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Imazio, M., Basso, C., Brucato, A. L., Klingel, K., Kuchynka, P., Lazaros, G. A., Merlo, M., Sinagra, G., Adler, Y., Bucciarelli‐Ducci, C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf222 · Cited by 12
The Promise of Real-World Data for Research — What Are We Missing?
Abbasi, A. B., Curtis, L. H., & Califf, R. M. (2025) · New England Journal of Medicine · doi:10.1056/nejmp2416479 · Cited by 12
COVID-19 mRNA Vaccine-Associated Myocarditis
Kyaw, H., Shajahan, S., Gulati, A., Synn, S., Khurana, S., Nazar, N., Shrestha, S., & Kerstein, J. (2022) · Cureus · doi:10.7759/cureus.21009 · Cited by 12
Cardiovascular manifestations secondary to COVID-19: A narrative review
Fauvel, C., Trimaille, A., Weizman, O., Pezel, T., Mika, D., Waldmann, V., Cohen, A. A., & Bonnet, G. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100904 · Cited by 13
Natural History of Myocardial Injury After COVID-19 Vaccine–Associated Myocarditis
Alhussein, M. M., Rabbani, M., Sarak, B., Dykstra, S., Labib, D., Flewitt, J. A., Lydell, C. P., Howarth, A. G., Filipchuk, N. G., Kealey, A. J., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.07.017 · Cited by 13
Giant cell myocarditis after first dose of BNT162b2 – a case report
Hirsch, V. G., Schallhorn, S., Zwadlo, C., Diekmann, J., Länger, F. P., Jonigk, D. D., Kempf, T., Schultheiß, H., & Bauersachs, J. K. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2590 · Cited by 13
Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
Shahid, R., Tang, W. H. W., Klein, A. L., Kwon, D. H., & Amdani, S. M. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.06.011 · Cited by 12
Coronavirus Disease-2019 Vaccine Hesitancy
Hammershaimb, E. A., Campbell, J. D., & O’Leary, S. T. (2022) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2022.12.001 · Cited by 11
Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination—A nationwide study
Su, W., Liu, Y., Chang, C., Lin, Y.-C., Huang, W., Wu, L., Chen, S.-F., Lin, Y.-S., Hsieh, Y.-L., Yang, C.-A., et al. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.01.016 · Cited by 11
2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases
Branch of Cardiovascular Physicians of Chinese Medical Doctor Association (2023) · Cardiology Plus · doi:10.1097/cp9.0000000000000043 · Cited by 13
COVID-19 vaccine-associated myocarditis: Analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature
Jaiswal, V., Mukherjee, D., Ang, S. P., Kainth, T., Naz, S., Shrestha, A. B., Agrawal, V., Mitra, S., Chia, J. E., Jilma, B., et al. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101280 · Cited by 13
A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge
Tian, Y., Deng, Z., Chuai, Z., Li, C., Chang, L., Sun, F., Cao, R., Yu, H., Xiao, R., Lü, S., et al. (2024) · Virology · doi:10.1016/j.virol.2024.110125 · Cited by 15
Vaccines for Respiratory Viruses—COVID and Beyond
Rajanala, K., & Upadhyay, A. (2024) · Vaccines · doi:10.3390/vaccines12080936 · Cited by 10
Do Long COVID and COVID Vaccine Side Effects Share Pathophysiological Picture and Biochemical Pathways?
Lesgards, J., Cerdan, D., & Perronne, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167879 · Cited by 13
COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection
Al-Kindi, S. G., & Zidar, D. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.005 · Cited by 10
Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology
Hamedi, K. R., Loftus, G., Traylor, L. B., Goodwin, R. L., & Arce, S. (2023) · Vaccines · doi:10.3390/vaccines11020362 · Cited by 13
Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study
Fan, M., Lai, F. T. T., Cheng, F. W. T., Tsie, N. T. Y., Li, X., Wan, E. Y. F., Wong, C. K. H., Chan, E. W., Yiu, K. H., Wong, I. C. K., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100745 · Cited by 11
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Mahasing, C., Doungngern, P., Jaipong, R., Nonmuti, P., Chimmanee, J., Wongsawat, J., Boonyasirinant, T., Wanlapakorn, C., Leelapatana, P., Yingchoncharoen, T., et al. (2023) · Vaccines · doi:10.3390/vaccines11040749 · Cited by 11
An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge
Honda-Okubo, Y., Li, L., Andre, G., Leong, K. H., Howerth, E., Bebin-Blackwell, A.-G., Ross, T., & Petrovsky, N. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.063 · Cited by 12
Similarities and differences between myocarditis following COVID-19 mRNA vaccine and multiple inflammatory syndrome with cardiac involvement in children
Amodio, D., Pascucci, G. R., Cotugno, N., Rossetti, C., Manno, E. C., Pighi, C., Rocchi, F., D’Alessandro, A., Perrone, M. A., Valentini, A., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109751 · Cited by 10
HLA binding‐groove motifs are associated with myocarditis induction after Pfizer‐BioNTech BNT162b2 vaccination
Aharon, A., Benedek, G., Barhoum, B., Parnasa, E., Magadle, N., Perzon, O., & Mevorach, D. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14142 · Cited by 11
Self-citation
Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants
Wang, R., Huang, X., Cao, T.-S., Sun, C., Luo, D., Qiu, H., Wu, M. L., Huang, X., Yu, C., Li, J., et al. (2022) · Virology · doi:10.1016/j.virol.2022.09.003 · Cited by 11
Cardiac complications of COVID-19 vaccination: now we know more
Verdecchia, P., Coiro, S., Notaristefano, F., Santucci, A., Angelis, F. D., D'Ammando, M., & Angeli, F. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac093 · Cited by 12
Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia
Deng, L., Eldik, A. V., O'Moore, M., Buttery, J. P., Cheung, A. W., Cox, N. R., Drake-Brockman, C., Dwyer, N., Effler, P. V., Gold, M., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01206-w · Cited by 11
Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency
Milota, T., Smetanová, J., Skotnicová, A., Rataj, M., Lašťovička, J., Zelená, H., Paračková, Z., Fejtková, M., Kanderová, V., Froňková, E., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.10.046 · Cited by 10
Post-COVID-19 vaccination myocarditis: a prospective cohort study pre and post vaccination using cardiovascular magnetic resonance
Ng, M., Tam, C. H., Lee, Y. P., Fong, H. T. A., Wong, C., Ng, W. K. C., Yeung, M. H. Y., Ling, W.-H. I., Tsao, S. S. L., Wan, E. Y. F., et al. (2023) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-023-00985-2 · Cited by 10
Age- and sex-stratified risks of myocarditis and pericarditis attributable to COVID-19 vaccination: a systematic review and meta-analysis
Kitano, T., Salmon, D. A., Dudley, M. Z., Saldanha, I. J., Thompson, D. A., & Engineer, L. D. (2024) · Epidemiologic Reviews · doi:10.1093/epirev/mxae007 · Cited by 10
Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance
Ferreira‐da‐Silva, R., Lobo, M. F., Pereira, A. M., Morato, M., Polónia, J. J., & Ribeiro‐Vaz, I. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1501921 · Cited by 11
Case Report: Two Case Reports of Acute Myopericarditis After mRNA COVID-19 Vaccine
Sciaccaluga, C., D’Ascenzi, F., Cameli, M., Gallotta, M., Menci, D., Antonelli, G., Banchi, B., Mochi, V., Valente, S., & Focardi, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.827237 · Cited by 10
COVID Vaccine-Associated Myocarditis in Adolescent Siblings: Does It Run in the Family?
Moosmann, J., Gentles, T. L., Occleshaw, C. J., & Mitchelson, B. (2022) · Vaccines · doi:10.3390/vaccines10040611 · Cited by 10
Systemic lupus erythematosus myocarditis after COVID-19 vaccination
Sogbe, M., Matteo, A. B.-D., Frisco, I. M. D., Bastidas, J. F., Salterain-González, N., & Gavira, J. J. (2022) · Reumatología Clínica · doi:10.1016/j.reuma.2022.06.003 · Cited by 11
A review of COVID vaccines: success against a moving target
Chong, S. H., Burn, L., Cheng, M. T. K., Warr, I. S., & Kenyon, J. C. (2022) · British Medical Bulletin · doi:10.1093/bmb/ldac025 · Cited by 9
Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk
Mahaux, O., Powell, G. E., Haguinet, F., Sobczak, P., Saini, N., Barry, A., Mustafa, A., & Bate, A. (2023) · Drug Safety · doi:10.1007/s40264-023-01306-3 · Cited by 10
Susceptibility of SARS-CoV2 infection in children
Cotugno, N., Amodio, D., Buonsenso, D., & Palma, P. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05184-w · Cited by 11
The Epidemiology of COVID-19 Vaccine-Induced Myocarditis
Costa, C., & Moniati, F. (2024) · Advances in Medicine · doi:10.1155/2024/4470326 · Cited by 10
Effects of BNT162b2 mRNA Covid-19 vaccine on vascular function
Yamaji, T., Harada, T., Hashimoto, Y., Nakano, Y., Kajikawa, M., Yoshimura, K., Goto, C., Han, Y., Mizobuchi, A., Yusoff, F. M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302512 · Cited by 10
Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination
Kawano, H., Motokawa, T., Kurohama, H., Okano, S., Akashi, R., Yonekura, T., Ikeda, S., Izumikawa, K., & Maemura, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9800-22 · Cited by 10
Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease
Shoji, K., Funaki, T., Yamada, M., Mikami, M., Miyake, K., Ueno, S., Tao, C., Myojin, S., Aiba, H., Matsui, T., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.09.013 · Cited by 10
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in JapanPreprint
Watanabe, S., & Hama, R. (2022) · medRxiv · doi:10.1101/2022.10.13.22281036 · Cited by 11
The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally
Caplanusi, I., Szmigiel, A., van der Elst, M. E., Christiansen, M. L. S., Thirstrup, S., Zaccaria, C., Cappelli, B., Genov, G., & Straus, S. M. J. M. (2024) · Drug Safety · doi:10.1007/s40264-024-01405-9 · Cited by 8
Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination
Fanti, S., Dyer, C., Ingimarsdóttir, I. J., Harding, D., Wang, G., d’Amati, A., Shahaj, E., Sigurbergsdóttir, A. Ý., Thórsdóttir, H. S., Gunnarsdóttir, O. B., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074644 · Cited by 11
mRNA-Based Therapeutics: Advances in Drug Delivery, Comparative Innovations, and Biomedical Applications
Joshi, R., Sharma, S., Kapoor, D. U., Prajapati, B. G., Huanbutta, K., & Sriamornsak, P. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00774 · Cited by 10
COVID-19 Vaccination-Induced Myopericarditis: An Imager’s Perspective
Bews, H. J., Bryson, A., Bortoluzzi, T., Tam, J. W., & Jassal, D. S. (2022) · CJC Open · doi:10.1016/j.cjco.2022.01.007 · Cited by 9
Consensus on COVID-19 Vaccination in Pediatric Oncohematological Patients, on Behalf of Infectious Working Group of Italian Association of Pediatric Hematology Oncology
Cesaro, S., Muggeo, P., Zama, D., Cellini, M., Perruccio, K., Colombini, A., Carraro, F., Petris, M. G., Petroni, V., Mascarin, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051235 · Cited by 8
Acute interstitial nephritis after vaccination with BNT162b2
Rieckmann, S., Seibert, F. S., Hogeweg, M., Bertram, S., Doevelaar, A. A. N., Amann, K., Babel, N., & Westhoff, T. H. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01275-3 · Cited by 9
Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?
Esposito, S., Caminiti, C., Giordano, R., Argentiero, A., Ramundo, G., & Principi, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915580 · Cited by 8
Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination
Pueyo, P. P., Ruberte, E. G., Ordás, J. G., Blanco, L. M., Pascual-Figal, D. A., Larrañaga-Moreira, J. M., Gómez-Barrado, J. J., Calle, D. G., Bonet, L. A., Salinas, G. L. A., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02225-0 · Cited by 9
Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination
Watson, R. A., Ye, W., Taylor, C. A., Jungkurth, E., Cooper, R. A., Tong, O., James, T., Shine, B. S. F., Hofer, M., Jenkins, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008151 · Cited by 11
Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance studyPreprint
Ouldali, N., Bagheri, H., Salvo, F., Antona, D., Pariente, A., Leblanc, C., Tebacher, M., Micallef, J., Lévy, C., Cohen, R., et al. (2022) · medRxiv · doi:10.1101/2022.01.17.22269263 · Cited by 9
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS
Mercolini, F., & Cesaro, S. (2022) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2022.009 · Cited by 9
SARS-CoV-2 vaccines and myocarditis
Sularz, A., Hua, A. X., & Ismail, T. F. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0049 · Cited by 8
Pathogenic Variants of Scavenger Receptor CD36 Lead to Decreased Efferocytosis and Predispose to Myocarditis Following Vaccination With Pfizer-BioNTech BNT162b2 Against Coronavirus Infection (COVID-19)
Canavati, C., Siam, A., Labes, S., Trabelsi, N., Regev, E., Parnasa, E., Barhoum, B., Magadle, N., Perzon, O., Braun, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.064884 · Cited by 8
Self-citation
The risk‐benefit ratio of Covid‐19 vaccines: Publication policy by retraction does nothing to improve it
Walach, H., Klement, R. J., & Aukema, W. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.35 · Cited by 8
Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever
Shechtman, L., Lahad, K., Livneh, A., Grossman, C., Druyan, A., Giat, E., Lidar, M., Freund, S., Manor, U., Pomerantz, A., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac131 · Cited by 8
Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review
Wu, C.-T., Chin, S., & Chu, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.856991 · Cited by 8
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Vanichsetakul, P., Thonginnetra, S., Niemsorn, K., Promsena, P., Tandhansakul, M., Kasemlawan, N., Ruangkijpaisal, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10050807 · Cited by 8
SARS-CoV-2 and the Vaccination Hype
Sangaletti, P., Doe, J., Gatti, A. M., Arvay, C. G., Giuliani, L., & Lettner, H. (2022) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v2i1.34 · Cited by 8
The benefits of COVID ‐19 vaccination programmes for children may not outweigh the risks
Abecasis, F. (2022) · Acta Paediatrica · doi:10.1111/apa.16430 · Cited by 8
Case report: Five patients with myocarditis after mRNA COVID-19 vaccination
Murase, H., Zhu, Y., Sakaida, K., Mizuno, H., Mori, H., Iwayama, H., Suzuki, N., Nagai, N., & Okumura, A. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.977476 · Cited by 8
Intricacies Affiliated With Post-COVID Vaccine Complications in Makkah Province, Saudi Arabia
Maqbul, M. S., Basalib, S. G., Mereani, M. J., Bakhsh, L. M., Alzamzami, B. A., & Garout, R. M. (2022) · Cureus · doi:10.7759/cureus.32749 · Cited by 6
Current evidence of COVID-19 vaccination-related cardiovascular events
Khiali, S., Rezagholizadeh, A., Behzad, H., Baghi, H. B., & Entezari‐Maleki, T. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2161249 · Cited by 8
Optic Neuritis After SARS-CoV-2 Vaccination
Shemer, A., Greenbaum, A., Toledano, A., Biron, R., Dubinsky‐Pertzov, B., & Or, L. (2023) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001811 · Cited by 8
Benefits v. risks of COVID-19 vaccination: an examination of vaccination policy impact on the occurrence of myocarditis and pericarditis
Carleton, B., Salmon, D. A., Ip, P., Wong, I. C. K., & Lai, F. T. T. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100797 · Cited by 8
Imaging Acute and Chronic Cardiac Complications of COVID-19 and after COVID-19 Vaccination
Tijmes, F. S., Marschner, C., de Matos, J. F. R. G., Fresno, C. M. U., Chacoff, J. M. G., Thavendiranathan, P., Fuss, C., & Hanneman, K. A. (2023) · Radiographics · doi:10.1148/rg.230044 · Cited by 8
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Perrotta, C., Fenizia, C., Carnovale, C., Pozzi, M., Trabattoni, D., Cervia, D., & Clementi, E. (2023) · Vaccines · doi:10.3390/vaccines11091481 · Cited by 9
Severe aplastic anaemia after serial vaccinations for SARS‐CoV‐2, pneumococcus and seasonal influenza
Wang, X., Laczko, D. I., Caponetti, G. C., Rabatin, S., & Babushok, D. V. (2022) · eJHaem · doi:10.1002/jha2.443 · Cited by 8
Vaccinating children and adolescents against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), updated data from Israel
Glikman, D., Stein, M., & Shinwell, E. S. (2021) · Acta Paediatrica · doi:10.1111/apa.16157 · Cited by 8
Immunomodulating and Immunosuppressive Therapy for Virus-Negative Immune-Mediated Myocarditis
Frustaci, A., Letizia, C., Alfarano, M., Marchionni, G., Verardo, R., & Chimenti, C. (2024) · Biomedicines · doi:10.3390/biomedicines12071565 · Cited by 8
Absence of cardiac impairment in patients after severe acute respiratory syndrome coronavirus type 2 infection: A long-term follow-up study
Salatzki, J., Ochs, A. G., Weberling, L. D., Heins, J., Zahlten, M., Whayne, J. G., Stehning, C., Giannitsis, E., Denkinger, C. M., Merle, U., et al. (2024) · Journal of Cardiovascular Magnetic Resonance · doi:10.1016/j.jocmr.2024.101124 · Cited by 7
Global epidemiology of myocarditis: disparities in age, sex and geography
Klingel, K., Tschöpe, C., Yon, D. K., Mensah, G. A., Weber, B. N., Kontorovich, A., Lee, S., Cooper, L. T., & Ammirati, E. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01276-w · Cited by 9
Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19
Heymans, S. R. B., Dawson, D. K., Fuster, V., Metra, M., & Tocchetti, C. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.003 · Cited by 7
A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database
Musa, H. H., & Musa, T. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135927 · Cited by 11
Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents
Lee, J. S., Choi, H., Shin, S. H., Hwang, M.-J., Na, S., Kim, J. H., Park, S., Yoon, Y., Kang, H. M., Ahn, B., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.032 · Cited by 7
SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database
Takada, K., Taguchi, K., Samura, M., Igarashi, Y., Okamoto, Y., Enoki, Y., Tanikawa, K., & Matsumoto, K. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.07.025 · Cited by 7
Myocarditis and Pericarditis are Temporally Associated with BNT162b2 COVID-19 Vaccine in Adolescents: A Systematic Review and Meta-analysis
Choi, Y., Lee, J. S., Choe, Y. J., Lee, H., Yoon, Y., Shin, S. H., Hwang, M.-J., Choi, H., Na, S., Kim, J. H., et al. (2024) · Pediatric Cardiology · doi:10.1007/s00246-024-03618-2 · Cited by 7
Myocarditis Post Moderna Vaccination: Review of Criteria for Diagnosis
McCullough, J., McCullough, J. P., Korlipara, G., & Kaell, A. T. (2021) · Cureus · doi:10.7759/cureus.19633 · Cited by 7
Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity
Liuzzo, G., & Volpe, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab901 · Cited by 7
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
Klamer, T. A., Linschoten, M., & Asselbergs, F. W. (2022) · Netherlands Heart Journal · doi:10.1007/s12471-022-01677-9 · Cited by 10
Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
Chellapandian, S. B., Türkmen, S., Salim, I., Chinnakaruppan, S., & Mohammad, J. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5741 · Cited by 7
Evaluation of neutrophil-to-lymphocyte ratio and immune response in patients vaccinated with Pfizer-Biontech vaccine
Mediu, R., Rama, A., & Puca, E. (2022) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.16310 · Cited by 8
Paving the Way Towards Precision Vaccinology: The Paradigm of Myocarditis After Coronavirus Disease 2019 (COVID-19) Vaccination
Lagousi, T., Papadatou, I., Strempas, P., Chatzikalil, E., & Spoulou, V. I. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac396 · Cited by 7
Health technology assessment to employ COVID-19 serological tests as companion diagnostics in the vaccination campaign against SARS-CoV-2
Tomaiuolo, R., Restelli, U., Faggiano, F. C., Resta, C. D., Albitar‐Nehme, S., Giuliani, F., Derrico, P., Ricciardi, W., Banfi, G., & Ritrovato, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0262 · Cited by 7
Fulminant myocarditis after the first dose of mRNA-1273 vaccination in a patient with previous COVID-19: a case report
Horiuchi, K., Kosugi, S., Abe, H., & Ueda, Y. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytac290 · Cited by 7
Case Series of Myocarditis Following mRNA COVID Vaccine Compared to Pediatric Multisystem Inflammatory Syndrome: Multicenter Retrospective Study
Aviel, Y. B., Hashkes, P. J., Dizitzer, Y., Inbar, K., Berkun, Y., Eisenstein, E. M., Saied, M. H., Goldzweig, O., Heshin‐Bekenstein, M., Ling, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081207 · Cited by 9
The Burden of Omicron Variant in Pakistan: An Updated Review
Khan, S., Khan, S., Haider, F., Malik, J., Khan, F., Khan, I., Ullah, I., Zia, M. A., & Kousar, S. (2022) · COVID · doi:10.3390/covid2100105 · Cited by 7
Risks of Myocarditis and Pericarditis Following Vaccination with SARS-CoV-2 mRNA Vaccines in Japan: An Analysis of Spontaneous Reports of Suspected Adverse Events
Kobayashi, H., Fukuda, S., Matsukawa, R., Asakura, Y., Kanno, Y., Hatta, T., Saito, Y., Shimizu, Y., Kawarasaki, S., Kihara, M., et al. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00466-1 · Cited by 7
Physician Perspectives on Vaccination in Patients With Autoimmune Inflammatory Rheumatic Diseases: An International Survey
Seo, P., Winthrop, K. L., Sawalha, A. H., Choi, S. R., Park, H. A., Hwang, W., Lee, E. B., & Park, J. K. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.220135 · Cited by 7
Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey
Minoia, F., Lucioni, F., Heshin‐Bekenstein, M., Vastert, S. J., Kessel, C., Uziel, Y., Lamot, L., Ruperto, N., Gattorno, M., Bracaglia, C., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1030083 · Cited by 9
Fulminant Myocarditis and Acute Appendicitis after COVID-19 Vaccination
Kawano, H., Yamamoto, N., Kurohama, H., Okano, S., Kurobe, M., Honda, T., Akashi, R., Yonekura, T., Ikeda, S., Izumikawa, K., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0680-22 · Cited by 7
Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
Pillsbury, A., Phillips, A., Deng, L., Quinn, H., Macartney, K. K., & Gidding, H. F. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.041 · Cited by 7
Systems vaccinology studies – achievements and future potential
Sugrue, J. A., & Duffy, D. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105318 · Cited by 8
A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2
Knowlton, K. U., Knight, S., Muhlestein, J. B., Le, V. T., Horne, B. D., May, H. T., Stenehjem, E. A., & Anderson, J. L. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab663 · Cited by 7
Cardiac inflammation associated with COVID-19 mRNA vaccination in patients with and without previous myocarditis
Kaufmann, C. C., Villatore, A., HEUGL, M., Kvakan, H., Zweiker, D., Sala, S., Mazzone, P., Huber, K., & Peretto, G. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.06204-4 · Cited by 7
Evolution in the Diagnosis and Treatment of Myocarditis in Recent Years: State of the Art
Campodonico, J., Lauri, C., Pezzuto, B., Agostoni, P., & Vignati, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217661 · Cited by 6
COVID-19 and Myocarditis: Trends, Clinical Characteristics, and Future Directions
Abumayyaleh, M., Schupp, T., Behnes, M., El‐Battrawy, I., Hamdani, N., & Akın, İ. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134560 · Cited by 8
Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health
Ertl, H. C. J., Currie, S. L., & Luber, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985382 · Cited by 6
Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models
Zirkenbach, V. A., Ignatz, R. M., Öttl, R., Cehreli, Z., Stroikova, V., Kaya, M., Lehmann, L., Preusch, M. R., Frey, N., & Kaya, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055011 · Cited by 6
SARS-CoV-2 spike receptor-binding domain is internalized and promotes protein ISGylation in human induced pluripotent stem cell-derived cardiomyocytes
Okuno, S., Higo, S., Kondo, T., Shiba, M., Kameda, S., Inoue, H., Tabata, T., Ogawa, S., Morishita, Y., Sun, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48084-7 · Cited by 6
Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database
Yan, L., & Zheng, G. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2423679 · Cited by 6

Authors: Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R., Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I., Saliba, W., Muhsen, K., Levi, Y., Green, M. S., Keinan-Boker, L., & Alroy-Preis, S.
Affiliations: Bar-Ilan University (IL)
From the Department of Internal Medicine B, Division of Immunology–Rheumatology, and Wohl Institute for Translational Medicine (D.M.) and the Departments of Cardiology (R.A., O.A.), Pathology (K. Meir), and Radiology (D.C.), Hadassah Medical Center, Braun School of Public Health (E.A.), Jesselson Integrated Heart Center, Shaare Zedek Medical Center (T.H., N.L.), and the Department of Family Medicine (I.M.), Faculty of Medicine, Hebrew University of Jerusalem, the Divisions of Epidemiology (E.A., N.C., E.J.H., E.N.), Patient Safety (S.O.-C., D.A.), and Medicine (I.L.), Israeli Ministry of Health (M.B., R. Dichtiar, D.N., Y.H., Y.L., L.K.-B., S.A.-P.), and Clalit Health Services (E.N., I.M.), Jerusalem, Israel Center for Disease Control, and Azrieli Faculty of Medicine, Bar-Ilan University (O.A.), Ramat Gan, the Department of Epidemiology and Preventive Medicine, School of Public Health (M.B., K. Muhsen), and Tel Aviv Sourasky Medical Center (R.B.-A.), Tel Aviv University, Tel Aviv, Ben Gurion University of ...
Corresponding author: Alroy-Preis, Sharon
ORCID: Mevorach, Dror
Bromberg, Michal
Haas, Eric J.
Levi, Nir
Dagan, Ron
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-12-02
Volume: 385
Issue: 23
Pages: 2140-2149
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2109730
PMC: PMC8531987
OpenAlex: W3204791524
Cited by: 599
References: 7
Citations by year: 2026: 29 · 2025: 39 · 2024: 84 · 2023: 125 · 2022: 280 · 2021: 41
FWCI: 88.83
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: New England Journal of Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: myocarditis, BNT162b2 mRNA vaccine, COVID-19 vaccination, vaccine adverse events, incidence, standardized incidence ratio, risk difference, second vaccine dose, young men, Israel, active surveillance, adverse event reporting, vaccine safety surveillance, COVID-19 mortality, SARS-CoV-2 variants, Omicron variant
MeSH terms: COVID-19, BNT162 Vaccine, Adolescent, Adult, Echocardiography, Female, Hospitalization, Humans, Israel, Male, Middle Aged, Myocarditis, Retrospective Studies, Comorbidity, Incidence, Age Distribution, Sex Distribution, Kaplan-Meier Estimate, Young Adult, Patient Acuity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks